Special Research Initiatives - Grant ID: SR140100001
Funder
Australian Research Council
Funding Amount
$35,000,000.00
Summary
The Juvenile Diabetes Research Foundation Australian Type 1 Diabetes Research Network and Program. This Proposal continues the development of the initial Type 1 Diabetes Clinical Research Network (CRN), launched by JDRF in June 2011 with a $5m grant from the Australian Government.
The principal goal of the CRN is to positively impact the life of people with T1D in Australia through the support and promotion of clinical research. A further electoral commitment of $35m over 5 years will enable f ....The Juvenile Diabetes Research Foundation Australian Type 1 Diabetes Research Network and Program. This Proposal continues the development of the initial Type 1 Diabetes Clinical Research Network (CRN), launched by JDRF in June 2011 with a $5m grant from the Australian Government.
The principal goal of the CRN is to positively impact the life of people with T1D in Australia through the support and promotion of clinical research. A further electoral commitment of $35m over 5 years will enable further progress towards finding a cure for T1D, including delivering better and faster access to new therapies and treatments that can help prevent and manage the disease.
Read moreRead less
Intervening In The Natural History Of Type 1 Diabetes: An Integrated Approach
Funder
National Health and Medical Research Council
Funding Amount
$9,466,000.00
Summary
This Program brings together four of Australia’s top type 1 diabetes clinical and lab-based research teams. The program has three intersecting themes. The first theme, pathogenesis, focuses on early life and understanding why type 1 diabetes develops. The second theme, prevention, seeks to identifying new drugs to stop the disease from occurring. The third theme, treatment, aims to improve therapies to replace the cells that are destroyed during the disease process.
Repurposing JAK Inhibitors To Treat Type 1 Diabetes
Funder
National Health and Medical Research Council
Funding Amount
$947,874.00
Summary
Type 1 diabetes occurs when the immune system mistakenly attacks and destroys insulin-producing beta cells in the pancreas. Beta cells have to respond to molecules called cytokines for T cells to be able to kill them. We have identified a drug, called a JAK inhibitor, which will block the effects of cytokines on beta cells and cells of the immune system. The goal of this work is perform pre-clinical assessment of this drug, and test whether it has effects on type 1 diabetes in people.
Gene therapy for islet transplantation. Improved understanding of aetiology of type I diabetes. Development of islet transplantation as a clinical therapeutic for type I diabetes. Improved efficacy of islet transplantation. Improved health for subjects with type I diabetes. Decreased diabetic complications. Improved quality of life for subjects with type I diabetes. Reduced burden on health system for management of diabetic complications for subjects with type I diabetes
Understanding and regulating autoimmune disease through the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kappaB) family transcription factor, v-rel reticuloendotheliosis viral oncogene homolog B (RelB). This program is well-aligned with the national research priority: Promoting and Maintaining Good Health. The disabling conditions rheumatoid arthritis and type 1 diabetes affect over 1% of Australia's population. They are incurable, so disability and the need for treatment p ....Understanding and regulating autoimmune disease through the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kappaB) family transcription factor, v-rel reticuloendotheliosis viral oncogene homolog B (RelB). This program is well-aligned with the national research priority: Promoting and Maintaining Good Health. The disabling conditions rheumatoid arthritis and type 1 diabetes affect over 1% of Australia's population. They are incurable, so disability and the need for treatment persist into old age and life expectancy is reduced. The program focuses on more effective and safer treatment, and future disease prevention, with immune therapy. This will have social and economic benefits to Australia. The research will advance Australia's intellectual leadership in Immunology, providing research training and career opportunities, and will lead to strong collaborations between basic scientists, clinicians and industry.Read moreRead less